Viatris Inc header image

Viatris Inc

VTRS

Equity

ISIN null / Valor 58198423

NASDAQ (2025-11-21)
USD 10.46+2.65%

Viatris Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Viatris Inc is a global healthcare company that specializes in providing a wide range of quality medications across various therapeutic areas. The company is dedicated to expanding access to these medications for people around the world, regardless of their location or situation. Viatris aims to empower individuals by ensuring they have access to trusted healthcare solutions.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (11.11.2025):

Viatris Inc. reported its third quarter 2025 financial results, showcasing steady overall revenues with notable shifts in its regional performance and product sales. The company delivered strong operational execution, refined capital allocation with $920 million returned year‐to‐date, and updated its full-year financial guidance, while also acknowledging pressures from lower gross margins and a decline in both adjusted net earnings and EPS compared to the prior year.

Revenue & Regional Performance

Total revenues for Q3 2025 reached $3.76 billion, with total net sales at approximately $3.75 billion. Developed Markets experienced a slight decline, while Emerging Markets grew by 7% and Greater China posted a 10% increase, highlighting a mixed regional performance that underscores the company’s dynamic global footprint.

Earnings & Margins

On the earnings front, Viatris Inc. reported a U.S. GAAP net loss of $128.2 million compared to a profit of $94.8 million in the prior year. Adjusted net earnings fell by 13% to $784.3 million and adjusted EPS declined by 11%, with gross margins also facing downward pressure, reflecting both market challenges and the impact of strategic investments.

Cash Flow & Capital Allocation

The company demonstrated disciplined capital allocation by returning more than $920 million to shareholders year-to-date, including $500 million in share repurchases. Despite a slight decline in U.S. GAAP net cash provided by operating activities, Viatris is on track with its commitment to return over $1 billion to shareholders in 2025, balancing growth initiatives with shareholder value.

Strategic Initiatives & Guidance Update

Viatris Inc. remains focused on its strategic priorities and operational execution, as evidenced by key regulatory submissions and the ongoing enterprise-wide strategic review aimed at unlocking operational efficiencies. The updated full-year financial guidance reflects narrowed ranges for key metrics, with estimated operating cash flows centered around $2.325 billion, as the company prepares for future growth in 2026 and beyond.

Summarized from source with an LLMView Source

Key figures

-21.1%1Y
-5.68%3Y
-38.9%5Y

Performance

37.1%1Y
31.2%3Y
34.5%5Y

Volatility

Market cap

12048 M

Market cap (USD)

Daily traded volume (Shares)

8,953,705

Daily traded volume (Shares)

1 day high/low

12.47 / 12.28

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Edwards Lifesciences Corp
Edwards Lifesciences Corp Edwards Lifesciences Corp Valor: 1065343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.24%USD 85.13
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%USD 101.12
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 13.91
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%SEK 260.90
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.18%SEK 342.20